Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / YGION Biomedical GmbH

Clinicaltrial registered12 Nov 2026

YGION Biomedical GmbH

12 Nov 2026: Trial registered · First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
12 Nov 2026
Title
First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma
Conditions
Glioblastoma
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Austria
Country
Austria
Reference
NCT07930338
Location
Austria
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at YGION Biomedical GmbH

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Austria

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.